Fierce Pharma
JUNE 7, 2024
Once hailed as an anti-aging magic bullet, telomerase has failed to live up to the hype as it was profiled in a | The FDA has approved Geron Corporation's Rytelo (imetelstat) to treat a group of bone marrow disorders called myelodysplastic syndrome (MDS). The approval is the first for the 33-year-old California biotech.
MedCity News
JUNE 7, 2024
The Consumer Financial Protection Bureau, which has been targeting debt collection practices, survives a Supreme Court challenge. The post SCOTUS Deals a Blow to Medical Debt Collectors appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 7, 2024
After fessing up to wire fraud charges, a former Takeda employee will be preparing for a sentencing hearing rather than walking down the aisle with $2.3 million garnered through a scheme to defraud | Priya Bhambi, 40, pled guilty to wire fraud charges after running a detailed scheme to scam Takeda into paying for non-existent services from a fake consulting firm.
MedCity News
JUNE 7, 2024
While firewalls, network monitoring and other security practices are imperative, it pays to give more thought to how to better secure endpoint computing. The post Preventative Care: The Right Approach to Improving Endpoint Security appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JUNE 7, 2024
With 25 launches planned through 2030, Boehringer Ingelheim is gearing up for a busy few years. | The company expects to introduce brigimadlin in dedifferentiated liposarcoma and zongertinib in HER2-mutated non-small cell lung cancer next year. The launches are part of the company's wider plan to bring 25 new products to the market by 2030.
MedCity News
JUNE 7, 2024
Medical device company Zeto received clearance for its EEG brain monitoring system. The system includes a user-friendly, comfortable EEG headset designed to be easily operated by any medical professional with minimal training. The post Zeto Receives FDA Clearance for Its User-Friendly EEG Brain Monitoring System appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JUNE 7, 2024
We call for our partners in practice, education, and industry to join this effort to make our healthcare settings safer for all patients. The post Healthcare Errors: It Is Time to Tackle Them, Not Tolerate Them appeared first on MedCity News.
pharmaphorum
JUNE 7, 2024
Nestle Health Science bids to take control of Seres Therapeutics’ oral microbiome product Vowst for preventing C. diff infections.
MedCity News
JUNE 7, 2024
Rapport Therapeutics’ IPO came with a concurrent private placement that boosted the biotech’s cash haul. The new capital will support clinical development of a lead drug with a novel approach to focal epilepsy, a form of the disorder that affects 1.8 million people in the U.S. The post Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test appeared first on MedCity News.
pharmaphorum
JUNE 7, 2024
UK group Cycle Pharma has made an unsolicited takeover bid to buy Vanda Pharma, which is already fending off an overture from Future Pak.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
JUNE 7, 2024
When it comes to consumer – and patient – preferences for payment options, security and speed reign supreme. The post Applying Non-health Payment Experiences to Healthcare appeared first on MedCity News.
European Pharmaceutical Review
JUNE 7, 2024
Friend or foe? Pharmaceutical companies ask themselves this question before embracing the latest technologies because every innovation comes with both opportunities and risks. Today, technological advancements in artificial intelligence (AI), machine learning (ML), digitalisation, and robotic manufacturing automation solutions stand to revolutionise R&D, clinical trials, and manufacturing in the pharmaceutical industry.
PharmaTimes
JUNE 7, 2024
Phase 2 trial reveals significant improvement in MASH patients
European Pharmaceutical Review
JUNE 7, 2024
New sub-analysis data from a Phase II clinical trial show that after 48 weeks of survodutide treatment, 83.0 percent of adults with liver fibrosis achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH). This is compared to 18.2 percent with placebo. With its novel mechanism of action, the glucagon/GLP-1 receptor dual agonist is the first to show this level of fibrosis benefit in a Phase II MASH trial following 48 weeks of treatment, according
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Scott Burrows
JUNE 7, 2024
In my journey as a keynote motivational speaker within the financial services industry, I’ve had the privilege of addressing esteemed organizations such as Merrill Lynch, Janney Montgomery, Morgan Stanley, Met Life, Farmers and Edward Jones, among others. Through these engagements, I’ve shared my life-transforming story and principles of success anchored in Vision, Mindset, and Grit.
European Pharmaceutical Review
JUNE 7, 2024
The first telomerase inhibitor has been approved by the US Food and Drug Administration (FDA). RYTELO ( imetelstat ) is authorised for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anaemia. The first-in-class oligonucleotide telomerase inhibitor is indicated for these patients who need four or more red blood cell units over eight weeks, who are unresponsive to or ineligible for erythropoiesis-stimulating agents (ESA).
MedCity News
JUNE 7, 2024
The Peterson Health Technology Institute recently released a report that evaluated eight musculoskeletal solutions: DarioHealth, Hinge Health, Kaia Health, Limber Health, Omada Health, RecoveryOne, Sword Health and Vori Health. The post Report: Virtual MSK Solutions Meaningfully Improve Outcomes appeared first on MedCity News.
PharmaTimes
JUNE 7, 2024
Early-stage endometriosis now visible through non-invasive imaging
pharmaphorum
JUNE 7, 2024
More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo. The US regulator has cleared Rytelo (imetelstat) for adults with lower-risk MDS who have transfusion-dependent anaemia and have stopped responding to or cannot be treated with erythropoiesis-stimulating agents (ESAs) like erythropoietin (EPO).
Pharmaceutical Commerce
JUNE 7, 2024
By marrying real-world evidence and AI, pharma stakeholders can identify new opportunities to tailor interventions in a way that is most impactful to patients—helping them overcome roadblocks in initiating and maintaining therapy.
Pharmaceutical Technology
JUNE 7, 2024
The US Food and Drug Administration (FDA) has criticised the state of Chinese pharma company Jiangsu Hengrui’s facilities in a newly released 483 form.
PharmaTech
JUNE 7, 2024
Lonza’s Joe Garrity and Jerry Jiang discuss the latest trends and challenges in commercializing new CGTs.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmacy Times
JUNE 7, 2024
A single dose of the vaccine showed long-lasting protection against RSV-associated lower respiratory tract disease in older adults.
PharmaTech
JUNE 7, 2024
Lonza’s Joe Garrity and Jerry Jiang discuss the importance of not only automating CGT manufacturing, but also standardizing across processes.
Pharmaceutical Technology
JUNE 7, 2024
The FDA is looking to ask questions about a change of primary endpoint, treatment cessation and mortality reporting from the donanemab trial.
Pharmaceutical Commerce
JUNE 7, 2024
The latest news for pharma industry insiders.
Pharmaceutical Technology
JUNE 7, 2024
The prognostic factor(s) driving outcomes at the initial stages of hepatocellular carcinoma remain unclear, complicating the treatment choice.
Pharmaceutical Commerce
JUNE 7, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora, offers his thoughts on industry pain points and where he envisions the market progressing in terms of its technological capabilities.
Pharmaceutical Technology
JUNE 7, 2024
Agomab Therapeutics has now secured a US Food and Drug Administration (FDA) orphan drug designation for IPF treatment AGMB-447.
Pharmaceutical Commerce
JUNE 7, 2024
Causal mediation analysis sought to determine how public hesitancy plays a role in the government procurement of certain vaccines.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
338 
Let's personalize your content